drugset / Trial / NCT02342379
TH-302 in Combination With Bevacizumab for Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
Timeline
- Start
- 2015-05
- Primary completion
- 2019-01-04
- Completion
- 2019-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Evofosfamide | Other / unclassified | 670 mg/m2 | — |